Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
about
Update in lung cancer and mesothelioma 2012Clinical use of crizotinib for the treatment of non-small cell lung cancerCrizotinib resistance: implications for therapeutic strategiesThe role of the ALK receptor in cancer biologyPrecision medicine in NSCLC and pathology: how does ALK fit in the pathway?Targeted therapies and immunotherapy in non-small-cell lung cancerTackling ALK in non-small cell lung cancer: the role of novel inhibitorsTyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsNon-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerNew treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinibRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCMolecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugsALK inhibitors in non-small cell lung cancer: the latest evidence and developmentsOncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer CellsALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistancePersonalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for CeritinibCrizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancerThe distinctive nature of adenocarcinoma of the lungProgress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancerTreating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyOvercoming resistance to targeted therapies in NSCLC: current approaches and clinical applicationMultiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic TargetsALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment optionsPredictive biomarkers in precision medicine and drug development against lung cancerCombating acquired resistance to tyrosine kinase inhibitors in lung cancerMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularTargeting cancer with kinase inhibitorsTargeting EML4-ALK driven non-small cell lung cancer (NSCLC)Targeted therapies in CLL: mechanisms of resistance and strategies for managementResistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategiesReview of the current targeted therapies for non-small-cell lung cancerTargeted therapies in development for non-small cell lung cancerCIViC databaseAcquired Resistance to Crizotinib from a Mutation in CD74 – ROS1The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung CancerMolecular pathology of non-small cell lung cancer: a practical guide.Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.Ceritinib in ALK-rearranged non-small-cell lung cancer.
P2860
Q24619675-00B59C95-BBD5-4E10-8AE1-D75C608A9F18Q24630466-C9536B24-C81D-47F1-A22D-8C0DBA6E0AF6Q26738381-E44AB44F-A083-4F08-9310-7A7185A1DF83Q26738384-17648E70-A5D6-4192-ADA6-31778DAC7555Q26738390-F320B55A-0758-4BF1-A97E-C7F310B47E19Q26738986-3640409E-E933-4CE7-9464-6D005F90CE8EQ26740329-CDB60E44-31C7-4277-BECB-C52B648F5657Q26741318-8A5E3596-9ABA-46A5-8026-838CC5CC6008Q26741814-05839D6D-515E-4D3B-8AA8-011F1FCF710CQ26745427-8D8ED77F-7104-4CCC-8CEE-C2605AFB8575Q26746230-49D11328-B548-42AC-95F6-6023C3697A4CQ26747276-A70D7335-AF63-4F7F-908F-F87D362589BAQ26769659-3D789F49-56A4-43AF-B780-28A587A4AF27Q26769879-DE18B4C8-77F1-40CE-90E8-97435B0D7F65Q26774625-87828DF2-A7E5-47CE-AC2D-8857786FB4ABQ26775347-7941E50F-1494-439E-A463-7600F8A6D637Q26775817-B0F846AF-87FC-4A75-AF85-2C286A317D63Q26778500-1477178B-CFC3-4448-9CAC-3E4E17F20D07Q26781159-EDB4CD85-A8B6-4FFB-BDA4-F2C8BA6EF5CDQ26784298-97CADD88-4538-4503-A143-3441FAE40255Q26795555-0675BF5B-2DBC-4684-BC80-BB860B5A01A8Q26795556-6D095094-C9A7-46E7-AC61-5006654BCB2BQ26795735-126E560D-F8E5-47C5-A2CF-FE478D806F50Q26820845-3967DA6F-FA0B-45DD-85D8-7476B36A9EFCQ26824536-1E726CA7-F8D4-4B79-AE6D-DC226400A197Q26824877-E4F13453-744B-4475-A499-5CD7904E3373Q26828860-E5DBD1B7-C6EC-4EA2-B565-B74A5A38CEF6Q26865765-1468B298-12DF-457B-A413-EE3BB3C2DAD2Q27002155-4E31D056-9725-498A-BB18-DE085545FAADQ27002528-D492F560-24A2-4945-9E3E-2931295DC500Q27004161-82975FA2-D1AD-473E-8E63-A135E6526A7CQ27015079-9EB75EF7-D3F3-4FB1-800B-53B25DE34362Q27022852-5DC61985-4963-47D1-A2E5-B2591771FE80Q27612411-95782CA2-7894-4F9F-9328-C3AF40C05B00Q27678436-BF574E7D-0643-488B-90D9-5B4C1DE6529CQ27682565-FE7C544C-56B1-4699-8B27-5F1D45AFF1F1Q27690919-AD861C67-EADE-487D-8DBC-E1F9C04E4835Q27852601-657C5A44-2362-44B3-B920-A8612908AD3FQ27852806-6B0BC43A-8513-4101-9943-828B9BAA2E10Q27852989-E9D08B16-53DB-457F-B0AF-2B8B81DAE1C9
P2860
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Mechanisms of resistance to cr ...... ed non-small cell lung cancer.
@ast
Mechanisms of resistance to cr ...... ed non-small cell lung cancer.
@en
Mechanisms of resistance to cr ...... ed non-small cell lung cancer.
@nl
type
label
Mechanisms of resistance to cr ...... ed non-small cell lung cancer.
@ast
Mechanisms of resistance to cr ...... ed non-small cell lung cancer.
@en
Mechanisms of resistance to cr ...... ed non-small cell lung cancer.
@nl
altLabel
Mechanisms of resistance to cr ...... ged non-small cell lung cancer
@en
prefLabel
Mechanisms of resistance to cr ...... ed non-small cell lung cancer.
@ast
Mechanisms of resistance to cr ...... ed non-small cell lung cancer.
@en
Mechanisms of resistance to cr ...... ed non-small cell lung cancer.
@nl
P2093
P2860
P3181
P1476
Mechanisms of resistance to cr ...... ged non-small cell lung cancer
@en
P2093
Amanda B Pilling
Andrew J Weickhardt
D Ross Camidge
Dara L Aisner
Derek J Linderman
Kimi L Kondo
Lynn E Heasley
Marileila Varella-Garcia
Robert C Doebele
P2860
P304
P3181
P356
10.1158/1078-0432.CCR-11-2906
P407
P577
2012-01-10T00:00:00Z